Answer
Starting rifampicin transiently increased ambrisentan exposure approximately twofold in healthy volunteers, but by day 8 there was no clinically relevant effect at steady state; patients taking ambrisentan should be closely monitored when starting rifampicin.
Sources for this answer
- Volibris 5 mg film coated tabletsGlaxoSmithKline UK · emc · SmPC §4.5 Interaction with other medicinal products · Version 28Document updated
Sources checked